Literature DB >> 11332987

Coxsackievirus-adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression.

Z You1, D C Fischer, X Tong, A Hasenburg, E Aguilar-Cordova, D G Kieback.   

Abstract

The expression of coxsackievirus-adenovirus receptor (CAR) and the integrins alpha(v)beta3 and alpha(v)beta5 was analyzed quantitatively (flow cytometry) and qualitatively (immunocytochemistry) in five human ovarian cancer cell lines (PEO1, PEO4, PEO14, SKOV-3, and OVCAR-3) and three control cell lines (293, HeLa, and CHO-K1). The transduction efficiencies were evaluated by adv/rsv-beta-Gal transduction followed by X-gal staining. The effects of 17beta-estradiol on cell growth, CAR and integrins alpha(v)beta3/5 expression, adenovirus transduction efficiency, and cell-killing efficacy of adv/rsv-tk plus ganciclovir were determined. The levels of CAR, integrin alpha(v)beta3, and integrin alpha(v)beta5 showed great variation between the cell lines. Whereas the expression of CAR appeared to be essential for and positively correlated with adenovirus transduction efficiency, the integrins alpha(v)beta3 and alpha(v)beta5 were not absolutely necessary for adenovirus transduction even though their presence may facilitate transduction. In PEO4 and PEO1 cells, proliferation was stimulated by 17beta-estradiol in a dose-dependent manner. In PEO4 cells, and much less pronounced in PEO1 cells, this was accompanied by an increase in CAR expression. The stimulation of CAR expression was paralleled by an increased transduction efficiency resulting in an increased cell-killing efficacy. Our data suggest that the expression of CAR is one of the most important prerequisites for successful adenovirus-mediated gene therapy of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11332987     DOI: 10.1038/sj.cgt.7700284

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  16 in total

1.  General strategy for broadening adenovirus tropism.

Authors:  Laura Fontana; Maurizio Nuzzo; Lorena Urbanelli; Paolo Monaci
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 2.  Getting genetic access to natural adenovirus genomes to explore vector diversity.

Authors:  Wenli Zhang; Anja Ehrhardt
Journal:  Virus Genes       Date:  2017-07-15       Impact factor: 2.332

3.  Protein transduction domains fused to virus receptors improve cellular virus uptake and enhance oncolysis by tumor-specific replicating vectors.

Authors:  Florian Kühnel; Bernd Schulte; Thomas Wirth; Norman Woller; Sonja Schäfers; Lars Zender; Michael Manns; Stefan Kubicka
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody.

Authors:  Elena A Kashentseva; Joanne T Douglas; Kurt R Zinn; David T Curiel; Igor P Dmitriev
Journal:  J Mol Biol       Date:  2009-03-13       Impact factor: 5.469

5.  Characterization of the expression of key adenoviral receptors CAR and integrin beta3/beta5 subunits on the membrane of human NT2 neurons.

Authors:  Deqi Huang; Angele Desbois; Gao Chen; Hung Fang; Sheng T Hou
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

6.  Presence of the coxsackievirus and adenovirus receptor (CAR) in human neoplasms: a multitumour array analysis.

Authors:  M Reeh; M Bockhorn; D Görgens; M Vieth; T Hoffmann; R Simon; J R Izbicki; G Sauter; U Schumacher; M Anders
Journal:  Br J Cancer       Date:  2013-09-10       Impact factor: 7.640

Review 7.  Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer.

Authors:  Rebeca Gonzalez-Pastor; Peter S Goedegebuure; David T Curiel
Journal:  Cancer Gene Ther       Date:  2020-09-19       Impact factor: 5.987

8.  Genetically modified adenoviral vector with the protein transduction domain of Tat improves gene transfer to CAR-deficient cells.

Authors:  Shihai Liu; Qinwen Mao; Weifeng Zhang; Xiaojing Zheng; Ye Bian; Dongyang Wang; Huijin Li; Lihong Chai; Junli Zhao; Haibin Xia
Journal:  Biosci Rep       Date:  2009-04       Impact factor: 3.840

Review 9.  Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.

Authors:  Hanni Uusi-Kerttula; Sarah Hulin-Curtis; James Davies; Alan L Parker
Journal:  Viruses       Date:  2015-11-24       Impact factor: 5.048

10.  Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy.

Authors:  S L Hulin-Curtis; H Uusi-Kerttula; R Jones; L Hanna; J D Chester; A L Parker
Journal:  Cancer Gene Ther       Date:  2016-05-27       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.